Streamline Patient Identification for Site Teams

Simplify the process of identifying eligible patients for the site’s clinical research team with our expertise and technology.

Patient Recruitment

2/3

of clinical trials fail to enroll the target sample of patients, leading to extended timelines and cancellations

67%

increase in registered studies in the last five years

217 Million

patients are treated annually by Q-Centrix hospital partners

Focus on Enrollment, Not Identification

With pre-screened patient lists, site teams can concentrate on engaging and enrolling patients, significantly reducing their workload and increasing efficiency.

Accelerate Your Trial Timeline

Reduce trial costs, minimize delays, and bring your product to market sooner with faster, high-quality recruitment.

Standardize Processes and Reduce Bias

Our consistent, efficient procedures are shared across our network, screening every possible patient, reducing recruitment delays, and ensuring smoother operations.

Q-Centrix simplifies patient recruitment through seamless data access and expert-driven processes.

Thorough data curation from our partner hospitals, conducted by over 1,000 clinical data experts.

Potential participants are identified as the data is transformed into structured, actionable data sets.

Our experts collaborate with site teams to ensure candidates are pre-screened and ready for enrollment.

This streamlined approach eliminates guesswork, reduces delays, and ensures that only the most qualified patients are considered.

Why Other Solutions Don’t Work

AI solutions can be useful but only if it’s guided by clinical expertise. The vast majority of AI are not trained on enough data to replace an experienced clinical expert’s screening capability.

Software solutions deployed at the site aren’t used by hospital staff due to a lack of resourcing.

Why Q-Centrix?

Related Insights

Ready to Streamline Your Patient Identification?

Contact Q-Centrix today to discuss how we can help you achieve faster, more efficient trials with pre-screened, eligible patients.